HK1021541A1 - Serine protease inhibitors - Google Patents

Serine protease inhibitors

Info

Publication number
HK1021541A1
HK1021541A1 HK99102658A HK99102658A HK1021541A1 HK 1021541 A1 HK1021541 A1 HK 1021541A1 HK 99102658 A HK99102658 A HK 99102658A HK 99102658 A HK99102658 A HK 99102658A HK 1021541 A1 HK1021541 A1 HK 1021541A1
Authority
HK
Hong Kong
Prior art keywords
protease inhibitors
serine protease
serine
inhibitors
protease
Prior art date
Application number
HK99102658A
Other languages
English (en)
Inventor
Anton Egbert Peter Adang
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of HK1021541A1 publication Critical patent/HK1021541A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/022—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/022—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
    • C07K5/0222—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2 with the first amino acid being heterocyclic, e.g. Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • C07K5/06113—Asp- or Asn-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK99102658A 1996-03-01 1999-06-22 Serine protease inhibitors HK1021541A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96200543 1996-03-01
PCT/EP1997/000938 WO1997031937A1 (en) 1996-03-01 1997-02-26 Serine protease inhibitors

Publications (1)

Publication Number Publication Date
HK1021541A1 true HK1021541A1 (en) 2000-06-16

Family

ID=8223736

Family Applications (1)

Application Number Title Priority Date Filing Date
HK99102658A HK1021541A1 (en) 1996-03-01 1999-06-22 Serine protease inhibitors

Country Status (26)

Country Link
US (1) US6410684B1 (xx)
EP (1) EP0886647B1 (xx)
JP (1) JP2000506837A (xx)
KR (1) KR19990087415A (xx)
CN (1) CN1212704A (xx)
AR (1) AR006310A1 (xx)
AT (1) ATE221080T1 (xx)
AU (1) AU709330B2 (xx)
BR (1) BR9707808A (xx)
CA (1) CA2246246A1 (xx)
CZ (1) CZ277898A3 (xx)
DE (1) DE69714222T2 (xx)
DK (1) DK0886647T3 (xx)
ES (1) ES2180933T3 (xx)
HK (1) HK1021541A1 (xx)
HU (1) HUP9900390A3 (xx)
IL (1) IL120310A (xx)
NO (1) NO983991L (xx)
NZ (1) NZ331484A (xx)
PL (1) PL328875A1 (xx)
PT (1) PT886647E (xx)
RU (1) RU2178419C2 (xx)
TR (1) TR199801704T2 (xx)
TW (1) TW442452B (xx)
WO (1) WO1997031937A1 (xx)
ZA (1) ZA971667B (xx)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19990082424A (ko) * 1996-02-13 1999-11-25 이.에이치. 리링크 세린 프로테아제 억제제
WO1998051684A1 (en) 1997-05-15 1998-11-19 Eli Lilly And Company Antithrombotic compound
DE69910762T2 (de) 1998-04-30 2004-03-11 Agouron Pharmaceuticals, Inc., La Jolla Antipicornavirale verbindungen, deren herstellung und verwendung
AU9031598A (en) * 1998-08-17 2000-03-06 Cortech, Inc. Serine protease inhibitors comprising alpha-keto heterocycles
US6849605B1 (en) 1999-03-05 2005-02-01 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of viral infections
AU3731400A (en) 1999-03-05 2000-09-21 Trustees Of University Technology Corporation, The Methods and compositions useful in inhibiting apoptosis
US6489308B1 (en) 1999-03-05 2002-12-03 Trustees Of University Of Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of nitric-oxide-induced clinical conditions
PL354030A1 (en) 1999-08-04 2003-12-15 Agouron Pharmaceuticals, Inc.Agouron Pharmaceuticals, Inc. Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
CN1525957A (zh) 2000-06-14 2004-09-01 ������ҩ�����޹�˾ 抗细小核糖核酸病毒的化合物与组合物,它们的药物用途,以及用于其合成的物质
US7244721B2 (en) 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
US7012066B2 (en) 2000-07-21 2006-03-14 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
CN1446201A (zh) * 2000-07-21 2003-10-01 先灵公司 用作丙型肝炎病毒ns3－丝氨酸蛋白酶抑制剂的新型肽
CA2436774A1 (en) 2001-01-30 2002-08-08 R. Michael Lawrence Sulfonamide lactam inhibitors of factor xa
US7405210B2 (en) * 2003-05-21 2008-07-29 Osi Pharmaceuticals, Inc. Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
ATE483708T1 (de) 2004-03-08 2010-10-15 Prosidion Ltd Pyrrolopyridin-2-carbonsäurehydrazide als inhibitoren von glykogenphosphorylase
ATE424821T1 (de) 2004-12-02 2009-03-15 Prosidion Ltd Pyrrolopyridin-2-karbonsäureamide
EP2344531B1 (en) * 2008-10-15 2014-12-10 Danisco US Inc. Modified variant bowman birk protease inhibitors
JP7164521B2 (ja) 2016-06-21 2022-11-01 オリオン・オフサルモロジー・エルエルシー 炭素環式プロリンアミド誘導体
UA124672C2 (uk) 2016-06-21 2021-10-27 Оріон Офтальмолоджі Ллс Гетероциклічні похідні пролінаміду
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4556655A (en) * 1984-09-24 1985-12-03 Schering Corporation Antihypertensive compounds having both diuretic and angiotensin converting enzyme inhibitory activity
ZW11290A1 (en) * 1989-07-14 1990-10-31 Smithkline Beecham Corp Hemoregulatory peptides
AU670381B2 (en) * 1993-04-30 1996-07-11 Merck & Co., Inc. Thrombin inhibitors
SE9301916D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
ZA951617B (en) * 1994-03-04 1997-02-27 Lilly Co Eli Antithrombotic agents.
ZA951618B (en) 1994-03-04 1996-08-27 Lilly Co Eli Antithrombotic agents
US5561146A (en) 1994-06-10 1996-10-01 Bristol-Myers Squibb Company Modified guanidino and amidino thrombin inhibitors
WO1995035311A1 (en) 1994-06-17 1995-12-28 Corvas International, Inc. 3-amino-2-oxo-1-piperidineacetic derivatives as enzyme inhibitors
JPH0820597A (ja) * 1994-07-07 1996-01-23 Meiji Seika Kaisha Ltd トロンビン阻害作用を有する複素環カルボニル化合物
MD970253A (ro) 1994-12-22 1999-05-31 Biochem Pharma Inc. Inhibitori biciclici micromoleculari ai trombinei

Also Published As

Publication number Publication date
DK0886647T3 (da) 2002-11-04
HUP9900390A3 (en) 2000-11-28
AR006310A1 (es) 1999-08-25
CA2246246A1 (en) 1997-09-04
BR9707808A (pt) 1999-07-27
PT886647E (pt) 2002-12-31
CN1212704A (zh) 1999-03-31
PL328875A1 (en) 1999-03-01
ES2180933T3 (es) 2003-02-16
IL120310A (en) 2002-02-10
IL120310A0 (en) 1997-06-10
DE69714222T2 (de) 2003-02-20
DE69714222D1 (de) 2002-08-29
EP0886647B1 (en) 2002-07-24
WO1997031937A1 (en) 1997-09-04
KR19990087415A (ko) 1999-12-27
TR199801704T2 (xx) 1998-12-21
NZ331484A (en) 2000-01-28
NO983991D0 (no) 1998-08-31
EP0886647A1 (en) 1998-12-30
JP2000506837A (ja) 2000-06-06
RU2178419C2 (ru) 2002-01-20
US6410684B1 (en) 2002-06-25
AU1877597A (en) 1997-09-16
ATE221080T1 (de) 2002-08-15
ZA971667B (en) 1997-09-10
HUP9900390A2 (hu) 1999-06-28
AU709330B2 (en) 1999-08-26
CZ277898A3 (cs) 1999-06-16
NO983991L (no) 1998-10-30
TW442452B (en) 2001-06-23

Similar Documents

Publication Publication Date Title
ZA983629B (en) Serine protease inhibitors
HUP9901187A3 (en) Serine protease inhibitors
PL336625A1 (en) Protease inhibitors
AU7127298A (en) Serine protease inhibitors
AP9701054A0 (en) Inhibitors of cycteine protease
PL347948A1 (en) Serine protease inhibitor
NZ331486A (en) Serine protease inhibitors
HK1021541A1 (en) Serine protease inhibitors
IL132088A0 (en) Protease inhibitors
EP1093367A4 (en) PROTEASE INHIBITORS
ZA983841B (en) Protease inhibitors
ZA983522B (en) Protease inhibitors
PL328223A1 (en) Aspartil protease inhibitors
ZA988479B (en) Protease inhibitors
EP1067894A4 (en) PROTHEASEINHIBITOREN
EP1079821A4 (en) PROTEASE INHIBITORS
GB9800817D0 (en) Serine protease inhibitors
GB9603217D0 (en) Serine protease inhibitors
ZA988064B (en) Protease inhibitors
EP1086083A4 (en) PROTEASE INHIBITORS
EP0975612A4 (en) PROTEASE INHIBITORS
GB9613719D0 (en) Serine protease inhibitors
ZA971178B (en) Serine protease inhibitors.
ZA977032B (en) Protease inhibitors
ZA983097B (en) Protease inhibitors

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20060226